Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2017—Bio-Rad Laboratories announced FDA clearance for its BioPlex 2200 ToRC IgM Assay, a fully automated assay for the detection of IgM class antibodies to Toxoplasma gondii, rubella, and cytomegalovirus offered in a multiplexed panel.
October 2017—Morphotek, a subsidiary of Eisai, has entered into a collaboration and license agreement with Fujirebio Diagnostics to validate and commercialize the CA125 II assay for use on the Lumipulse system as a companion diagnostic to aid in the selection of ovarian cancer patients who may best respond to farletuzumab.
October 2017—TechLab received FDA clearance for the Tri-Combo Parasite Screen test. The test is an enzyme immunoassay for the simultaneous qualitative detection of Giardia spp., Cryptosporidium spp., and/or E. histolytica antigen in human fecal specimens. It specifically detects pathogenic E. histolytica and does not cross-react with nonpathogenic E. dispar.
October 2017—Seegene presented its Seegene Random Access System at the 69th AACC Annual Clinical Lab Expo in San Diego. The system provides order to report on the same day by simultaneously performing high multiplex real-time PCR testing on a single platform, regardless of specimen type or assays.
October 2017—The Center for Phlebotomy Education has published The Lab Draw Answer Book. The book provides answers to more than 400 questions commonly asked by health care professionals about drawing, handling, and processing blood samples for laboratory tests.
October 2017—BioMérieux announced that BacT/Alert Virtuo, its fully automated blood culture system, has received 510(k) clearance from the FDA and is commercially available in the United States and in countries that recognize the CE mark.
October 2017—Beckman Coulter Diagnostics and partner Diazyme Laboratories announced FDA clearance of a new procalcitonin (PCT) assay for the management of bacterial infections and sepsis.
October 2017—Formulatrix announced the release of its next-generation Constellation Digital PCR System. The digital PCR system mimics contemporary qPCR with a plate-based and high-throughput workflow capable of processing up to four plates per run. For higher throughput applications such as gene expression analysis, plates that accommodate 96 samples will provide partitioning into 8,000 microfluidic chambers per sample.
October 2017—Aim Lab Automation Technologies unveiled at the AACC annual meeting the PathFinder 350D, the latest PathFinder automation platform for decapping and sorting incoming blood collection tubes directly into various analyzer racks ready for analysis.
October 2017—Biocartis Group announced the availability of its Idylla platform in the United States. The Idylla is a fully automated, walkaway, real-time PCR system with a hands-on time of less than two minutes. Its access on-demand design and assay turnaround time of between 90 and 150 minutes allow pathologists to analyze samples at any time, without the need for batching or for trained operators, in virtually any laboratory. The Idylla console and instrument are class II exempt.
